A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Lennox-Gastaut syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms GWPCARE4
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
    • 13 Apr 2017 According to a GW Pharmaceuticals media release, data will be presented at the 2017 American Academy of Neurology Annual Meeting.
    • 05 Dec 2016 According to a GW Pharmaceuticals media release, data from this trial presented at the 70th Annual Meeting of the American Epilepsy Society 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top